Novus Biologicals products are now on bio-techne.com

CRISPR/Cas9 Knockout Lysates and Cell Lines

Related Links

Knockout Cell Lines from B-MoGen

CRISPR-Cas9 FAQs

5 Pillar Validation

WB Handbook

WB Resources

Loading Control Handbook

KO Antibody Validation

HeLa cells and Ki-67 Knockout (KO) HeLa cells were stained with anti-human Ki-67 antibody


Custom Knockout (KO) Cell Lines are available through our sister company B-MoGen Biotechnologies, Inc.

Request Your Knockout Cell Line from B-MoGen »



CRISPR/Cas9 Knockout Lysates

The clustered regularly interspaced short palindromic-associated protein 9 system (CRISPR-Cas9) provides a powerful tool to specifically and efficiently introduce genomic-modifications. Specificity is encoded by a single-guide RNA (sgRNA), which targets Cas9 nuclease to genes of interest leading to double strand breaks. Subsequently, recall of DNA repair mechanisms introduce insertions and deletions (indels) which efficiently lead to bi-allelic mutations and gene silencing.1

Application of this cutting-edge CRISPR/Cas9 gene-editing technology for the generation of knockout cell lysates and cell lines ensures the development of useful tools to validate antibody specificity and elucidate gene function.

The use of genetic negative controls has been proposed by the International Working Group for Antibody Validation as one of five key criteria for ensuring antibody specificity.2 Specificity, selectivity and fidelity of antibody-target interactions often varies based on the intricacies of specific analytical applications (e.g., immunoblot vs. immunostaining). Double knockout cell-lysates (Western Blot-WB) and cell-lines (Immunocytochemistry-ICC) are the best negative controls to quickly and confidently prove an antibody’s specificity for a target of interest and ensure reproducibility.3


KO Lysates

In WB analysis, an initial indicator of antibody specificity is the presence of a single band at the expected target size, however proper antibody validation requires the use of adequate controls.

Western blot analysis of Lactate Dehydrogenase B (LDHB) in HEK293 cell lysate and LDHB knockout (KO) HEK293 cell line using Lactate Dehydrogenase B (LDHB) antibody

Genetic Strategies Validation. Knockout Validated: Lactate Dehydrogenase B Antibody [NBP2-53421] - Western blot shows lysates of 293 human embryonic kidney parental cell line and LDHB knockout (KO) 293 cell line. PVDF membrane was probed with 1 ug/ml of Rabbit Anti-Human LDHB Polyclonal Antibody (Catalog # NBP2-53421) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog #HAF008). Specific band was detected for LDHB at approximately 35 kDa (as indicated) in the parental 293 cell line, but is not detectable in the knockout 293 cell line. This experiment was conducted under reducing conditions.


Because CRISPR/Cas9 gene-editing technology enables complete removal or "knock out" of both alleles of the gene encoding the target protein, antibody specificity is confirmed by demonstrating that a protein band is only present in the wildtype and not the KO cell lysate in WB analysis. To confirm differential expression, it is also important to analyze a separate target protein as a loading control (e.g., GAPDH) to demonstrate that all samples were loaded and transferred equally across wells.

Novus continues to support efforts geared at ensuring antibody specificity by adding more KO validated data to our antibody datasheets. Take your research a step further with B-MoGen's genome-wide selection of knockout cell lines.


Useful applications include:



Request your Knockout Cell Line from B-MoGen »



  1. Peng, J., Zhou, Y., Zhu, S., & Wei, W. (2015). High-throughput Screens in Mammalian Cells Using the CRISPR-Cas9 System. The FEBS Journal, 1–8. https://doi.org/10.1111/febs.13251
  2. Uhlen, M., Bandrowski, A., Carr, S., Edwards, A., Ellenberg, J., Lundberg, E., … Yamamoto, T. (2016). A proposal for validation of antibodies. Nature Methods. https://doi.org/10.1038/nmeth.3995
  3. Bordeaux, Jennifer et al. “Antibody Validation.” BioTechniques 48.3 (2010): 197–209. PMC. Web. 24 May 2018